Ernexa Therapeutics Reports $1.2 Million Net Loss in Q3 2025, Revenue Declines to Zero

Ernexa Therapeutics Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $1.2 million, a significant reduction from the $26.6 million loss recorded in the same period last year. For the nine months ending September 30, 2025, the company incurred a net loss of $12.6 million, down from $38.8 million in the prior year. The company did not generate any revenue during the third quarter or the first nine months of 2025, contrasting with revenues of $487,000 and $581,000 for the same periods in 2024. The absence of revenue is attributed to the assignment of a customer contract to Factor Bioscience, which has since taken over the related obligations.

Total operating expenses for the third quarter of 2025 were $1.99 million, a decrease from $2.81 million in the previous year. This decline was primarily driven by a reduction in general and administrative expenses, which fell to $958,000 from $3.38 million, largely due to decreased legal fees and the termination of a sublease. Research and development expenses remained relatively stable, increasing slightly to $1.04 million from $1.00 million year-over-year. The company recognized a gain of $734,000 from the extinguishment of time-barred liabilities, contributing to the overall reduction in net loss.

Ernexa's cash position improved, with cash and cash equivalents totaling approximately $3.05 million as of September 30, 2025, compared to $1.73 million at the end of 2024. The company raised $7.2 million in gross proceeds from the sale of common stock and prefunded warrants during the nine months ended September 30, 2025. This capital was utilized to repay promissory notes totaling $2.3 million. The company reported a net cash used in operating activities of $5.87 million for the nine months, a notable improvement from $12.29 million in the prior year.

Strategically, Ernexa has focused on advancing its lead product candidate, ERNA-101, which is in preclinical development for cancer treatment. The company is also exploring partnerships to co-develop or out-license its therapeutic assets and is actively seeking research grants. However, the company has expressed substantial doubt regarding its ability to continue as a going concern, indicating that it will need to secure additional capital to fund operations over the next twelve months. The management has outlined potential avenues for raising funds, including public or private equity offerings and strategic partnerships, but acknowledges the uncertainty surrounding these efforts.

Looking ahead, Ernexa aims to complete Investigational New Drug (IND) enabling studies for ERNA-101 and submit the IND application by 2026, with plans to initiate a Phase I clinical trial in the same year. The company is also investigating additional therapeutic candidates, including ERNA-201 for inflammatory and autoimmune disorders. Despite the challenges, Ernexa remains committed to its mission of developing scalable, affordable cell therapies to address significant medical needs.